A novel nasal treatment developed to boost the natural human immune system to fight common colds and flu has proved remarkably successful in reducing COVID-19 viral replication test results, released today, reveals.
The novel product, INNA-051, being developed by Australian biotech company, Ena Respiratory, reduced viral replication by up to 96 percent in a gold-standard animal study led by Public Health England’s (PHE) Deputy Director, Professor Miles Carroll and published today on biomedical pre-publication research site, medRxiv.
